Tests inulin fiber supplement in adults with type 1 diabetes
Tests whether an inulin fiber supplement affects glucose control in adults with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Effect of Inulin Supplementation on Glycaemic Control and Immunological Parameters in Type 1 Diabetes (2024)
Key facts
- Where
- Amsterdam, NetherlandsSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07050888, who can take part
Where in Netherlands
- Amsterdam UMCAmsterdam, NetherlandsTaking people
- Diabeter Centrum AmsterdamAmsterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Trial code
- NCT07050888
- Record updated
- 3 July 2025
- Original description
The goal is to establish the effect of oral inulin supplementation on continuous glucose monitoring (CGM) metrics and immunological parameters in adults with type 1 diabetes. The investigators will perform a double-blind, randomized, placebo-controlled trial in 2x38 participants to measure effects on CGM metrics, gut microbiome composition, residual beta cell and immunological parameters.Read full original descriptionShow less
Effect of Inulin Supplementation on Glycaemic Control and Immunological Parameters in Type 1 Diabetes (2024)
The goal is to establish the effect of oral inulin supplementation on continuous glucose monitoring (CGM) metrics and immunological parameters in adults with type 1 diabetes. The investigators will perform a double-blind, randomized, placebo-controlled trial in 2x38 participants to measure effects on CGM metrics, gut microbiome composition, residual beta cell and immunological parameters.
Inclusion: A diagnosis of type 1 diabetes, as made by their primary clinician; A time in range of <80% in the last four weeks before screening.
Exclusion: Use of any fibre supplementation (within the last month before screening or ongoing); Use of antibiotics in the lasts three months before screening or during study period; Illicit drug use (e.g. MDMA/amphetamine/cocaine/heroin/GHB) in the past three months or use during the study period; Active infection during the study visit; Active inflammatory bowel disease; Inability or unwillingness to donate feces or urine; Inability or unwillingness to provide informed consent; Absence of a large bowel (ie colostomy).